Lupin to Invest $250M in New Florida Manufacturing Facility for Critical Respiratory Medicines

Global pharmaceutical leader Lupin announced plans for a new state-of-the-art manufacturing plant in Coral Springs, Florida, investing $250 million over five years. The facility will produce more than 25 critical respiratory medicines, including albuterol inhalers for children with asthma, creating over 200 jobs by 2030. The expansion strengthens Lupin's position as a global respiratory leader, enhances domestic manufacturing, and diversifies the supply chain, ensuring affordable, reliable access to lifesaving treatments.